Skip to Main content Skip to Navigation
Journal articles

IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer

Margaux Hubert 1 Elisa Gobbini 1, 2 Coline Couillault 1 Thien-Phong Vu Manh 3 Anne-Claire Doffin 1 Justine Berthet 1 Céline Rodriguez 1 Vincent Ollion 1 Janice Kielbassa 4 Christophe Sajous 5 Isabelle Treilleux 5 Olivier Tredan 5 Bertrand Dubois 1 Marc Dalod 3 Nathalie Bendriss-Vermare 1, 6 Christophe Caux 1, 6, 5 Jenny Valladeau-Guilemond 1, 7
1 UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon
2 CHU Grenoble Alpes - Centre Hospitalier Universitaire Grenoble Alpes
3 CIML - Centre d'Immunologie de Marseille - Luminy
4 Synergie Lyon Cancer [Lyon]
5 Centre Léon Bérard [Lyon]
6 LabEx DEVweCAN - Développement Cancer et Thérapies Ciblées [Lyon]
7 Labex_IRMIA - Institut de Recherche en Mathématiques, Interactions et Applications
Abstract : Dendritic cells play a key role in the orchestration of antitumor immune responses. The cDC1 (conventional dendritic cell 1) subset has been shown to be essential for antitumor responses and response to immunotherapy, but its precise role in humans is largely unexplored. Using a multidisciplinary approach, we demonstrate that human cDC1 play an important role in the antitumor immune response through their capacity to produce type III interferon (IFN-λ). By analyzing a large cohort of breast primary tumors and public transcriptomic datasets, we observed specific production of IFN-λ1 by cDC1. In addition, both IFN-λ1 and its receptor were associated with favorable patient outcomes. We show that IFN-III promotes a TH1 microenvironment through increased production of IL-12p70, IFN-γ, and cytotoxic lymphocyte–recruiting chemokines. Last, we showed that engagement of TLR3 is a therapeutic strategy to induce IFN-III production by tumor-associated cDC1. These data provide insight into potential IFN- or cDC1-targeting antitumor therapies.
Document type :
Journal articles
Complete list of metadatas
https://hal-amu.archives-ouvertes.fr/hal-02998632
Contributor : Anita Dumenil <>
Submitted on : Monday, November 30, 2020 - 11:59:09 AM
Last modification on : Wednesday, February 24, 2021 - 11:26:05 AM
Long-term archiving on: : Monday, March 1, 2021 - 6:50:07 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2021-05-30

Please log in to resquest access to the document

Identifiers

Collections

UNIV-AMU | UNIV-LYON1 | CRCL | CNRS | UDL | SITE-ALSACE

Citation

Margaux Hubert, Elisa Gobbini, Coline Couillault, Thien-Phong Vu Manh, Anne-Claire Doffin, et al.. IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer. Science Immunology, American Association for the Advancement of Science, 2020, 5 (46), pp.eaav3942. ⟨10.1126/sciimmunol.aav3942⟩. ⟨hal-02998632⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

54